airway inflammation lunginfection
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
2 Years to 99 Years
Inclusion criteria
Inclusion criteria: All patients with COPD, CF or CAP who are admitted to the Erasmus MC will be asked to participate in this study. The treating lung physician will assess eligibility.;COPD - Age >/= 18 years - Diagnosis of COPD according to GOLD criteria (FEV1/FVC/= 18 years - Clinical presentation of an acute illness with symptoms indicating CAP: fever, dyspnoea, cough, pleuritic chest pain and new consolidations on chest X-ray have to be present. - Normoxemic - In case of hypoxemia (O2 saturation /= 18 years - Diagnosis of CF confirmed by sweat-test and/or DNA analysis and/or electrophysiology testing - Stable phase (no signs of exacerbation) - Exacerbation phase: characterized by signs of increased coughing, increased sputum production, dyspnea, fatigue;In some circumstances children with CF have to undergo a bronchoscopy for diagnostic reasons. In these cases we will ask the patients and/or their parents whether some extra material can be obtained from bronchoscopy for this study. Importantly, the children will not be approached to undergo a bronchoscopy, only for scientific reasons!;When patients have to undergo lungtransplantation, they will be asked whether material from their lungs can be used for this study. ;Healthy individuals - Age >/= 18 years - No signs of any disease - Normal Lungfunction - Normal Chest X-ray;In case children with CF are included with age
Exclusion criteria
Exclusion criteria: CAP: - Hypoxemia (O2 saturation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to assess whether Th17 cell lineage is critically involved in COPD, CF and pneumonia pathogenesis. Therefore, we will (a) Analyse cytokine production by activated T cells that are present in the lungs of COPD and CF patients, as compared with activated T cells involved in host defense in pneumonia. (b) Analyse cytokine production by antigen-experienced/memory T cells that are present in the peripheral blood of COPD and CF patients, as compared with activated T cells involved in host defense in pneumonia. (c) Analyse whether naive T cells from COPD and CF patients are predisposed to Th17 polarization, when compared with naive T cells from control groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective is to investigate whether Th17 activity correlates with the presence of autoreactive B cells in COPD. Therefore, we will (a) Determine the presence of auto-antibodies in COPD patients. (b) Determine the repertoire of B cells presents in the lungs of COPD patients, as compared with B cells involved host defense in pneumonia. (c) Correlate the presence of Th17 differentiation with the presence of auto-immune B cells. Another secondary objective is to investigate whether in patients with pneumonia pneumococcal infections provoke a different inflammatory response than atypical pathogens. Therefore, we will Correlate the presence of Th17 cells and cytokine production by activated T cells with different pathogens causing pneumonia | — |
Countries
Netherlands
Outcome results
None listed